Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Given Consensus Rating of “Moderate Buy” by Brokerages

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has earned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $43.60.

A number of research firms have commented on COLL. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Piper Sandler reduced their target price on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. Finally, Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a report on Friday, January 10th.

Insider Activity

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the business’s stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $33.04, for a total value of $908,600.00. Following the completion of the sale, the executive vice president now directly owns 119,184 shares in the company, valued at approximately $3,937,839.36. The trade was a 18.75 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Scott Dreyer sold 2,255 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the transaction, the executive vice president now owns 124,421 shares in the company, valued at approximately $3,732,630. This trade represents a 1.78 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 109,193 shares of company stock valued at $3,243,594. 3.98% of the stock is owned by company insiders.

Institutional Investors Weigh In On Collegium Pharmaceutical

Institutional investors and hedge funds have recently bought and sold shares of the company. New Age Alpha Advisors LLC acquired a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at approximately $40,000. TD Private Client Wealth LLC raised its position in Collegium Pharmaceutical by 39.5% during the third quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after purchasing an additional 483 shares in the last quarter. KBC Group NV lifted its stake in Collegium Pharmaceutical by 72.5% during the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock worth $67,000 after purchasing an additional 982 shares during the last quarter. Virtus Fund Advisers LLC boosted its holdings in shares of Collegium Pharmaceutical by 30.5% in the 4th quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock valued at $69,000 after purchasing an additional 565 shares in the last quarter. Finally, Nisa Investment Advisors LLC increased its stake in shares of Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after purchasing an additional 316 shares during the last quarter.

Collegium Pharmaceutical Trading Up 0.5 %

Shares of NASDAQ:COLL opened at $29.71 on Friday. Collegium Pharmaceutical has a 52-week low of $27.28 and a 52-week high of $42.29. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The company has a market capitalization of $935.45 million, a P/E ratio of 12.81 and a beta of 0.99. The company has a 50-day simple moving average of $30.36 and a 200 day simple moving average of $32.45.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. The company had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. Sell-side analysts forecast that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.